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Summary
Human papillomavirus (HPV) vaccines containing types 16 and 18 are likely to be effective in
preventing cervical cancer associated with these HPV types. No information currently exists in
Botswana concerning the HPV types causing precancerous or cancerous lesions. Our goal was to
determine the prevalence of HPV types associated with precancerous cervical intraepithelial
neoplasia (CIN) stages 2 and 3 in HIV-infected women in Gaborone, Botswana. HIV-infected
women referred to our clinic with high-grade intraepithelial lesion on the Pap smear were enrolled
in the study. HPV typing was only performed if the histopathology results showed CIN stage 2 or
3 disease using linear array genotyping (CE-IVD, Roche Diagnostics).One hundred HIV-infected
women were identified with CIN stages 2 or 3 between August 11, 2009 and September 29, 2010.
Eighty-two of 100 women enrolled had coinfection by multiple HPV subtypes (range, 2 to 12). Of
the remaining 18 women, 14 were infected with a single high-risk subtype and 4 had no HPV
detected. Overall, 92 (92%) women were infected with at least 1 high-risk HPV subtype, and 56
were coinfected with more than 1 high-risk HPV type (range, 2 to 5). Fifty-one (51%) women had
HPV subtypes 16, 18, or both. HPV 16 and 18 are the most common types in HIV-infected
women with CIN 2 or 3 in Gaborone, Botswana, suggesting that the implementation of HPV
vaccination programs could have a significant impact on the reduction of cervical cancer
incidence. However, given the relative lack of knowledge on the natural history of cervical cancer
in HIV-infected women and the significant prevalence of infection and coinfection with other
high-risk HPV types in our sample, the true impact and cost-effectiveness of such vaccination
programs need to be evaluated.
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Cervical cancer is a preventable cause of morbidity and mortality worldwide and the most
common cancer among women in Sub-Saharan Africa (1–3). It is estimated that
approximately 250,000 women die from cervical cancer each year, 80% of them living in
resource-limited countries (1). The incidence of cervical cancer in Botswana is estimated at
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22.2/100,000 in 2008, making it the most common cancer among women in Botswana and
second in terms of cancer mortality in both sexes after Kaposi sarcoma (4,5).
Cervical cancer is associated with persistent human papillomavirus (HPV) infection, which
is the most common sexually transmitted infection in the world (6). However, the risk of
progression to cancer varies depending on the HPV subtype. Subtypes considered to have
the highest oncogenic risk are HPV 16, 18, 31, 33, 45, 52, and 58, with subtypes 16 and 18
being implicated in approximately 70% of cervical cancers worldwide (6–8). HPV types 35,
39, 51, 58, 59, 68, 73, and 82 have also been associated with the development of cervical
neoplasia (6–8). Low-risk subtypes, usually leading to the development of nonmalignant
lesions, are 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 89. Limited data exist for the HPV
types 26, 53, and 66 (6,8,9).
Immunocompetent individuals have low and slow rates of progression to cervical cancer,
partly secondary to an appropriate suppression of HPV replication (10–12). In contrast,
premalignant lesions in HIV-infected individuals seem to progress more rapidly and are
associated with higher morbidity and mortality (13). Rates of infection and abnormal
cytology increase as CD4+ T-cell counts decrease, as do the number of oncogenic HPV
subtypes involved in infection (14–17). In addition, the longer life span associated with
increased access to lifesaving antiretroviral therapy (ART) permits progression to cancer in
more patients (13,18).
Determining the frequency of HPV subtypes is important to evaluate the potential impact of
an HPV vaccine, particularly as the life expectancy of patients with HIV infection from the
region increases. There is limited information of the distribution of HPV subtypes causing
precancerous or cancerous lesions in HIV-infected women in Sub-Saharan Africa and no
information currently exists in Botswana, one of the countries most severely affected by the
HIV pandemic (9,19). The goal of this study was to determine the HPV subtypes detected in
HIV-infected women with precancerous cervical intraepithelial neoplasia (CIN) stages 2 and
3 in Gaborone, Botswana.
Materials and Methods
Setting
This study was implemented at the Botswana-UPenn Partnership Women's Health Clinic
located within the Princess Marina Hospital, the largest referral hospital in the country.
Study Design and Participant Enrollment
We conducted a descriptive study to determine the prevalence of HPV subtypes in HIV-
infected women in Botswana. HIV-infected women referred to our clinic with high-grade
intraepithelial lesion on the Pap smear were enrolled in the study. All HIV-infected adult
women (aged 21 yr or older) with CIN2 or CIN3 were eligible for enrollment. Women were
enrolled consecutively as they arrived at the clinic. All women were referred by the treating
physician (no self-referrals). Enrollment continued until the predetermined sample size of
100 women with histopathologic CIN2 or CIN3 was accrued.
Specimen Collection and Processing
Two specimens were obtained from all participants. Dry cervical swabs and tissue
specimens preserved in formalin were shipped daily to the Bioanalytical Research Center in
Johannesburg, South Africa, at room temperature. All processing and testing of samples
occurred at this site. HPV testing was performed exclusively on cervical swab specimens
from women who had histopathology results showing CIN2 or CIN3 disease. Swabs were
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lysed in 500 μL of the kit lysis buffer for 30 minutes at room temperature. The MagNa Pure
external lysis protocol was used to extract DNA from the lysis buffer into a 100-μL eluate.
Fifty microliters of the eluate was used for screening (Roche Amplicor HPV test; Roche
Diagnostics, Branchburg, NJ) and 50-μL eluate was used for genotyping (Roche Linear
Array Genotyping test; Roche Diagnostics) (1,20,21). Two internal control probes for high-
and low-level expression of the human beta-globin gene were run on each strip of DNA
extraction and amplification. Results were considered acceptable only if both internal
controls were clearly visible. None of the 100 samples had a negative internal betaglobin
polymerase chain reaction control; therefore, all positive results were genotyped. This
standardized polymerase chain reaction-based method can detect 13 high-risk HPV
genotypes (i.e. genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and 24 low-
risk HPV genotypes (i.e. genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70,
71, 72, 73, 81, 82, 83, 84, IS39, and CP6108).
Variables, Data Sources, and Measurement
All demographic, clinical and behavioral data were collected prospectively using
standardized questionnaires administered by the study personnel. Clinical data regarding
HIV history were also abstracted from the electronic medical records.
Sample Size
The sample size of 100 participants was selected based on the fact that it is possible that
types 31, 33, 35, 45, 52, 56, 58, or other HPV types occasionally detected in cervical cancers
may predominate in Botswana. On the basis of a precision of point estimate of a prevalence
of 50% for HPV type 16 or 18 infection, 100 samples would enable us to detect 50 cases
caused by type 16 or 18, with a 95% confidence interval to detect between 40 and 60 cases.
Statistical Analysis
Data analysis was carried out using STATA 11.0 (StataCorp, College Station, TX).
Comparisons were performed using the Mann-Whitney rank sum test or the Student t-test
according to the distribution of the variables. Association between variables was determined
by χ2 tests.
Results
A total of 100 HIV-infected women were identified with CIN stage 2 or 3 between August
11, 2009 and September 29, 2010. All patients invited to participate in the study consented
for enrollment. The median age was 36 years (interquartile range, 33–39 yr) and the mean
and median CD4+ T-cell count at the time of CIN2 or CIN3 diagnosis were 458.5 (95%
confidence interval, 414.9–502.2) and 420 cells/mm3 (interquartile range, 295–579 cells/
mm3), respectively. The mean and median CD4+ T-cell count of women at the time of HIV
diagnosis increased significantly by the time they were diagnosed with CIN2 or CIN3
(P<0.001). Table 1 lists the main demographic characteristics of the women enrolled in this
study.
Forty-nine of 100 (49%) women with premalignant lesions had the diagnosis of CIN 2,
whereas 51 (51%) had CIN3. One or more HPV subtypes were isolated from 96 (96%)
women. Ninety-two (92%) women had coinfection with multiple HPV subtypes (range, 2–
12), at least one of them being a high-risk subtype. Fifty-six (56%) women were coinfected
with more than 1 high-risk HPV subtype (range, 2–5) (Fig. 2).
All women infected with a single subtype had a high-risk HPV subtype (Figs. 1, 2). Among
these women, 4 were infected with HPV 16, 2 with HPV 18, 1 with HPV 33, 3 with HPV
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35, 1 with HPV 45, and 3 with HPV 52 (Fig. 1). Fifty-one (51%) women had HPV types 16
or 18 and 4 (4%) had both subtypes. Among the other high-risk subtypes, HPV subtypes 33,
35, and 58 were the most prevalent, detected in 18, 40, and 35 participants, respectively
(Fig. 3). The probe for HPV subtype 52 can lead to false-positive reports of HPV types 33,
35, and 58 by cross-reactivity. The number of coinfections with HPV subtype 52 was
evaluated to assess potential misclassification. Five of the 8 women infected with HPV
subtype 52 were also infected with HPV subtypes 33, 35, or 58, suggesting possible false-
positive reports for these 3 subtypes.
Discussion
High-risk HPV subtypes were found in 92% of the patient samples. Together, HPV 16 and
18 were the most common types in HIV-infected women with CIN2 or CIN3 in Gaborone,
Botswana, found in 51% of the women, with 8% having coinfection with both subtypes.
This prevalence is similar to other reports in resource-limited settings (6,9,19,22–26,28). In
Sub-Saharan Africa, this prevalence varies from 43% to 90% in HIV-negative women and
from 53% to 68% in HIV-infected women (19,27,28). Other high-risk HPV subtypes
account for approximately half of the CIN2 or CIN3 lesions in Botswana. Consistent with
reports from the region, HPV subtypes 35 and 58 were highly prevalent (19,27,28). Multiple
reports have documented an increase in the worldwide prevalence of HPV subtypes 52 and
58 over the last decade (29). Although the high prevalence of HPV subtype 58 in our sample
is consistent with this world trend, it may be an overestimation secondary to cross-reactivity
with HPV type 52. However, due to the high percentage of women coinfected with HPV
subtype 52 and HPV subtypes 33, 35, or 58, we believe the degree of misclassification
secondary to cross-reactivity was not high in our study (30).
Coinfection with multiple HPV subtypes was common. However, the significance of these
findings on the risk for progression to cervical cancer is unknown as our study was not
designed to distinguish persistent versus transient HPV infections. Other investigators have
reported an increase in coinfection with different HPV subtypes in HIV-infected women
compared with HIV-negative women (17,23,31). It remains to be determined whether this
finding is secondary to higher risk sexual practices, increased predisposition to infection,
decreased clearance of HPV, or other undefined factors in HIV-infected women (32).
The mean and median CD4+ T-cell count at the time of HIV diagnosis, in this sample, was
low (238 CD4+ cells/mm3) and it significantly increased by the time when CIN2 or CIN3
was diagnosed (458 CD4+ cells/mm3). This increase in CD4+ T-cell count is likely a
reflection of the large number of women who were either taking ART at the time of CIN2 or
CIN3 diagnosis, or had taken ART in the past. In addition, the mean number of years that
these women were on ART by the time of CIN2 or CIN3 diagnosis (3.4 yr) would allow
enough time for immune reconstitution. The effect of ART on the natural history of cervical
cancer remains unknown. As opposed to other HIV-associated conditions, most studies
suggest that the administration of ART has no effect on cervical cancer prevention (18,33).
Although our study was not designed to look at the role of ART on the development of
CIN2 or CIN3, the fact that the CD4+ T-cell counts were high (458) and 73% of women
were on ART is consistent with the hypothesis that ART does not prevent progression to
cervical cancer.
This cross-section of women treated in one clinic is likely representative of HIV-infected
women diagnosed with CIN2 and CIN3 in Botswana (4,5). The demographics and general
characteristics of our samples were comparable with those reported in prior series evaluating
the distribution of HPV subtypes in Sub-Saharan Africa and with those of women diagnosed
with premalignant cervical lesions through routine screening in Botswana and in the region
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(1,4,5). The mean and median age of women in our sample were similar to those reported in
other Sub-Saharan studies (1,3,19,34).
Progression to cervical cancer has been universally associated with persistent HPV
infection, and in particular, infection with high-risk HPV subtypes. Therefore, the failure to
identify any HPV subtype on 4 (4%) samples and a high-risk HPV subtype on 4 (4%)
additional samples likely represents false-negative results, even though a highly sensitive
HPV DNA polymerase chain reaction-based technology was used for detection and HPV
typing. However, secondary to the overall high rate of identification of HPV subtypes, and
in particular, the high frequency of identification of multiple subtypes in single samples, we
believe the impact of false-negative results on our estimates is likely minimal. The relatively
small number of samples tested also decreased the accuracy of our point prevalence
estimates and the generalizability of our results and suggests the need for larger studies to
confirm our findings.
This study is the first report of the prevalence and distribution of HPV subtypes among HIV-
infected women diagnosed with CIN2 or CIN3 in Botswana. Our results are consistent with
previous reports from the region and suggest that vaccination for HPV subtypes 16 and 18
could potentially prevent at least half of the cervical cancers in the country. However, the
current limited knowledge regarding the natural history of cervical cancer in patients
infected with HIV prevents us from drawing stronger conclusions. Given the relatively
unknown role of infection, coinfection, and reinfection with HPV subtypes other than 16 and
18 on cervical carcinogenesis in HIV-infected individuals, the true impact of HPV
vaccination on cervical cancer in settings similar to ours is difficult to predict and needs to
be evaluated. The high prevalence of primary infection, coinfection, and reinfection with
other HPV subtypes should be taken into consideration and be monitored if vaccination
programs are to be implemented, as other subtypes may replace HPV 16 and 18 as major
causes of cervical cancer and decrease the impact and cost-effectiveness of such
interventions.
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Fig. 1.
Number of human papillomavirus subtypes causing infection or coinfection per women.
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Fig. 2.
Number of high-risk human papillomavirus subtypes causing infection or coinfection per
women.
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Fig. 3.
Overall frequency of human papillomavirus subtypes.
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Table 1
Basic demographics and patient's characteristics
Median/Number Interquartile Range/Percentage
Age 36 (33–39)
Latest CD4 cell count cells/mm3 420 (295–579)
CD4 cell count at the time of HIV diagnosis 192 (84–346)
Time on HAART (yr) 3.4* (2.84-3.97)†
HAART
 Never taken 9 (9%)
 Taken in the past (not now) 18 (18%)
 Currently on HAART 73 (73%)
*
Mean.
†95% confidence interval.
HAART indicates highly active antiretroviral therapy.
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